Topic - Presenter
Welcome
Karl Mahler, Head of Investor Relations and Roche Group Planning
Pharma Strategy: Sustainable growth, more patient benefits, and less cost to society
Bill Anderson, Chief Executive Officer Roche Pharmaceuticals
Commercial Opportunities
Teresa Graham, Head of Pharma Global Product Strategy
Late Stage Pipeline Oncology & Non-malignant Hematology
Levi Garraway, Chief Medical Officer and Head Global Product Development
Late Stage Pipeline Neuroscience
Paulo Fontoura, Global Head Neuroscience and Rare Diseases Clinical Development
Late Stage Pipeline Immunology & Ophthalmology
Cristin Hubbard, Head I2O (Immunology, Infectious Diseases, Ophthalmology) Global Product Strategy
Infectious Disease: A close look at the HBV pipeline
John Young, Global Head of Infectious Diseases, Roche Pharma Research & Early Development
Late Stage Infectious Diseases: Influenza & SARS-CoV-2
Cristin Hubbard, Head I2O (Immunology, Infectious Diseases, Ophthalmology) Global Product Strategy
Appendix
Pipeline overview
Patient populations